CSIMarket Company Name, Ticker, Competitors, else..
 
Ocugen Inc   (NASDAQ: OCGN)
Other Ticker:  
 
 
Price: $0.8501 $-0.03 -3.748%
Day's High: $0.8832 Week Perf: -2.1 %
Day's Low: $ 0.85 30 Day Perf: -10.52 %
Volume (M): 736 52 Wk High: $ 2.11
Volume (M$): $ 626 52 Wk Avg: $1.16
Open: $0.88 52 Wk Low: $0.36



 Market Capitalization (Millions $) 236
 Shares Outstanding (Millions) 278
 Employees 47
 Revenues (TTM) (Millions $) 9
 Net Income (TTM) (Millions $) -40
 Cash Flow (TTM) (Millions $) 14
 Capital Exp. (TTM) (Millions $) 3

Ocugen Inc
Ocugen Inc. is a biopharmaceutical company based in the United States that specializes in developing gene therapies to treat rare inherited eye diseases. The company's main focus is on developing a potential cure for blindness-causing diseases, such as Retinitis Pigmentosa and Leber Congenital Amaurosis. Ocugen Inc. utilizes its own proprietary technology platform, known as OcuGene, to create gene therapies that aim to correct or replace defective genes in the eye. The company is actively involved in conducting clinical trials to evaluate the safety and efficacy of its gene therapies. Ocugen Inc. also collaborates with various research institutions and partners to advance its pipeline of therapeutic candidates.


   Company Address: 11 Great Valley Parkway Malvern 19355 PA
   Company Phone Number: 328-4701   Stock Exchange / Ticker: NASDAQ OCGN


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
ADVM   -1.83%    
AURA   -1.83%    
BLUE   -42.96%    
DNLI        3.33% 
FENCF        3.33% 
RGNX        5.72% 
• View Complete Report
   



Product Service News

?Ocugen Pioneering Paths in Gene Therapy for Rare Retinal Diseases,

Published Wed, Nov 20 2024 12:30 PM UTC

In an era where breakthroughs in biotechnology can redefine treatment landscapes for debilitating conditions, Ocugen, Inc. (NASDAQ: OCGN) is making significant strides with its gene therapy candidates targeting rare retinal diseases. This article will delineate Ocugen s recent accomplishments, particularly the European Medicines Agency (EMA) s granting of orphan medicinal pr...
Clinical Study

Promising Horizons Insights into Ocugens OCU410 Gene Therapy for Geographic Atrophy Related to Dry Age-Related Macul...

Published Tue, Nov 19 2024 12:03 PM UTC

The recent announcement from Ocugen, Inc. regarding their preliminary findings from the OCU410 ArMaDa clinical trial sheds light on a potential breakthrough in treating geographic atrophy (GA), secondary to dry age-related macular degeneration (dAMD). As the prevalence of dAMD continues to rise globally, innovative therapies like OCU410 are pivotal in paving the way for bett...
Management Announcement

Ocugen Secures $30 Million in Debt Funding While Rebounding from FDA Clinical Hold on Key Diabetes Treatment

Published Thu, Nov 7 2024 11:31 AM UTC

In a notable turn of events, Ocugen, Inc. (NASDAQ: OCGN), a biotechnology firm distinguished by its commitment to the discovery, development, and commercialization of pioneering gene and cell therapies, biologics, and vaccines, has recently fortified its financial position. As of November 6, 2024, Ocugen entered into a new $30 million credit facility with Avenue Venture Oppo...
Management Announcement

Ocugen?s OCU200: Hope Renewed as Clinical Hold Lifted, Yet Investment Challenges Persist

Published Wed, Oct 9 2024 10:31 AM UTC

In a significant development for the biotech sector, Ocugen, Inc. (NASDAQ: OCGN) has announced that the U.S. Food and Drug Administration (FDA) has lifted the clinical hold on its investigational new drug application for the Phase 1 clinical trial of OCU200. This recombinant fusion protein, a novel therapeutic approach combining tumstatin and transferrin, is aimed at address...
Clinical Study

Ocugen Completes Dosing in Phase 1/2 GARDian Trial for Stargardt Disease Gene Therapy, Faces Financial Challenges Ahe...

Published Wed, Aug 28 2024 10:31 AM UTC

Ocugen Advances Gene Therapy for Stargardt Disease as Phase 1/2 GARDian Trial Dosing Concludes In a significant development for the biotechnology sector, Ocugen, Inc. (NASDAQ: OCGN) has announced the completion of dosing in the high-dose cohort of its ongoing Phase 1/2 GARDian clinical trial, which is evaluating OCU410ST (AAV-hRORA), a promising modifier gene therapy designe...






Ocugen Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com